Indapamide: A Technical Review — From Synthetic-Route Impurities to the New Nitrosamine Regulatory Landscape

More Than Just a "Diuretic" Antihypertensive

Indapamide (CAS 26807-65-8; molecular formula C16H16ClN3O3S; molecular weight 365.83) is an indoline-based sulfonamide derivative originally developed by Servier (France) and marketed under brand names including Natrilix, Fludex and Lozol. Indications: it is used mainly for the treatment of essential hypertension, either as monotherapy or in combination with other antihypertensives; some formulations are also used for oedema associated with chronic congestive heart failure.

Indapamide, CAS 26807-65-8

Pharmacologically it is classified as a "thiazide-like" diuretic antihypertensive. Although it does not contain the benzothiadiazine ring of the classical thiazides, its mechanism is dual in nature: first, it inhibits the Na⁺–Cl⁻ cotransporter (NCC) in the distal convoluted tubule to produce diuresis; second, it exerts a direct calcium-antagonist-like relaxant effect on vascular smooth muscle. At the usual therapeutic doses, the latter effect is the more prominent of the two.

Compared with the classical thiazides, indapamide has a more neutral effect on lipid and glucose metabolism, but dose-dependent electrolyte disturbances — hypokalaemia in particular — remain a risk, so serum potassium should be monitored routinely. Clinically it is also frequently used in fixed-dose combinations with ACE inhibitors such as perindopril for blood-pressure control.

Key Impurities from the Perspective of the Synthetic Route

From a process-chemistry standpoint, the classical synthesis of indapamide starts from 2-methylindoline:

• 2-Methylindoline is nitrosated to give 2-methyl-1-nitrosoindoline (EP Impurity A);

• this nitroso intermediate is reduced with lithium aluminium hydride to give 1-amino-2-methylindoline (EP Impurity C);

• the latter undergoes acylation (hydrazide formation) with 4-chloro-3-sulfamoylbenzoyl chloride to give indapamide.

This means that EP Impurities A and C are not merely degradation products: they derive directly from the synthetic route itself as process intermediates, and inadequate purification control readily leaves them behind as residues. Impurity A (2-methyl-1-nitrosoindoline), because of the chiral carbon on the indoline ring together with the E/Z isomerism characteristic of N-nitroso compounds, actually exists in the form of four stereoisomers — a point that has been systematically characterised in recent chiral-HPLC enantiomer-separation studies. Impurity C (1-amino-2-methylindoline), an N-aminoindoline bearing a hydrazine-type structural fragment, is classified as a potential genotoxic impurity and its limit must be tightly controlled in accordance with the ICH M7 guideline.

In addition, the EP also covers the principal degradation product of indapamide — Impurity B (4-chloro-N-(2-methyl-1H-indol-1-yl)-3-sulfamoylbenzamide) — which can be detected under acidic, basic, photolytic and oxidative forced-degradation conditions, making it a key target for monitoring in stability studies and related-substances testing.

The Nitrosamine Regulatory Spotlight: Why Indapamide Is "On the List"

Since N-nitrosodimethylamine (NDMA) was detected in valsartan in 2018, regulatory attention to nitrosamine impurities has continued to escalate worldwide. Under the ICH M7 and Article 5(3) review framework, the European Medicines Agency (EMA) and the European Directorate for the Quality of Medicines & HealthCare (EDQM) require companies to carry out systematic nitrosamine risk assessments for active substances and to establish acceptable intakes (AIs) using approaches such as the Carcinogenic Potency Categorization Approach (CPCA).

Against this background, indapamide is one of the few drugs for which a specific N-nitrosamine test method and limit are already laid down directly in a Ph. Eur. monograph. In its official communication on the "new strategy for N-nitrosamine impurities in Ph. Eur. monographs", issued in early 2025, the EDQM listed indapamide together with gliclazide, molsidomine and triethanolamine as representative substances for which dedicated nitrosamine testing has been established.

The nitrosamine risk for indapamide does not arise only from process intermediates such as Impurity A. Attention must also be paid to nitrosamine drug substance-related impurities (NDSRIs), which regulators have focused on heavily in recent years. The defining feature of this class is that the nitrosamine is not formed from an extraneous small-molecule amine, but may instead arise from nitrosation of a specific nitrogen-containing motif within the drug substance molecule itself.

Structurally, the indapamide molecule contains an acylhydrazide-type N–N motif, so the formation of NDSRIs such as N-nitroso indapamide is theoretically possible. This risk mechanism is broadly similar to the NDSRI issues identified in recent years for drugs such as varenicline (Champix®), nortriptyline and sertraline: where the drug substance itself contains nitrosatable structures such as secondary amines or hydrazine groups, residual nitrite in excipients — or suitable nitrosation conditions during manufacture and storage — may generate the corresponding nitrosamine impurity.

For finished-dose manufacturers, therefore, nitrosamine risk assessment should not focus solely on low-molecular-weight nitrosamines introduced through starting materials or the manufacturing process. It should also take the chemical structure of the drug substance itself into account, systematically evaluating its potential to form NDSRIs, and whether excipients, manufacturing processes and storage conditions might promote the formation of such impurities.

CATO's Impurity and Reference Standard Solutions for Indapamide

Faced with this complex impurity profile and increasingly stringent compliance requirements, laboratories' demand for high-purity, structurally well-defined and traceable reference standards continues to rise. Guangzhou CATO Research Chemicals Inc. (CATO) has established a reference-standard portfolio covering indapamide's synthetic route, degradation pathways and nitrosamine risk points, with a product line of more than 50 SKUs. Representative products are listed below:

表 1Product list

As a reference-material manufacturer accredited to ISO 17034 under both CNAS (RM0030) and ANAB (AR-2832), CATO subjects every batch of indapamide-related reference standards to triple structural confirmation by HPLC, NMR and MS, and its COA discloses measurement uncertainty at ±2.0% (95% CI). Standard pack sizes ship the same day from stock, while custom or non-standard synthesis takes approximately 4–6 weeks — providing end-to-end reference-standard support for pharmacopoeial testing, stability studies and nitrosamine risk assessment.

For further product details, please contact CATO.

Selected References

• EDQM. New strategy for N-nitrosamine impurities in Ph. Eur. monographs, 2025. www.edqm.eu

• European Medicines Agency. Nitrosamine impurities, overview page. www.ema.europa.eu

• CAS DataBase / ChemicalBook. Indapamide (26807-65-8) synthesis route. www.chemicalbook.com

• Stereoselective HPLC separation and configurational stability study of the N-nitrosamine impurity of indapamide. PubMed 41420970.

• Chemical stability and interactions in a new antihypertensive mixture containing indapamide (EP impurity A/B identification). RSC Advances, DOI: 10.1039/C8RA06707D.

• British Pharmacopoeia Commission, EAG MC2 meeting minutes (Indapamide Impurity C genotoxicity note).

• Formation of N-Nitrosamine Drug Substance Related Impurities in Medicines: A Regulatory Perspective. Org. Process Res. Dev., ACS Publications, 2023.

• MedKoo Biosciences / LGC Standards / Santa Cruz Biotechnology — Indapamide (CAS 26807-65-8) identity data.

• FDA. Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities (NDSRIs), Guidance for Industry, Aug 2023. www.fda.gov

• BOC Sciences / Wikidata — Indapamide EP Impurity A racemate (CAS 85440-79-5) and (R)-/(S)-isomer identities (CAS 77083-49-9 / 77083-50-2).

• Clearsynth / TLC Standards / QCC Standards — Dehydro Indapamide-d3 (CAS 1185057-48-0) product identity records.

• ScienceDirect Topics. Indapamide — an overview; Drugs.com. Indapamide Side Effects (lipid-neutral profile, dose-dependent hypokalaemia incidence).

• A Deeper Investigation of Drug Degradation Mixtures Using a Combination of MS and NMR Data: Application to Indapamide. Molecules 2019, 24(9), 1764. MDPI (impurity B formation confirmed under acidic/basic/oxidative forced degradation).